About The Study: In a cohort composed primarily of women with obesity, glucagon-like peptide-1 receptor agonist (GLP-1RA) use with subsequent pre-pregnancy or early pregnancy discontinuation was associated with more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy.
Corresponding Authors: To contact the corresponding authors, email Jacqueline Maya, MD, ( jmaya@mgh.harvard.edu ) and Camille E. Powe, MD, ( camille.powe@mgh.harvard.edu ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.20951)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.20951?guestAccessKey=585472d4-fd5f-4365-9e38-a1599ead515e&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112425
JAMA